Search Bar & Filters
Found 47 Actively Recruiting clinical trials
Actively Recruiting
This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of AMO959 combined with lutetium 177Lu vipivotide tetraxetan AAA617 and androgen receptor pathway inhibitors ARPIs in adult men with PSMA-positive metastatic castration resistant prostate cancer mCRPC. This study includes participants who have failed one prior ARPI treatment, with or without previous taxane chemotherapy exposure. The study has two phases Phase Ib focuses on safety and dosing, and Phase II evaluates preliminary efficacy. The study consists of two phases. Phase Ib includes three dose level groups assessing AMO959 alone first, then combined with AAA617 and ARPI abiraterone or enzalutamide. Dose escalation meetings determine the recommended dose for expansion. Phase II randomizes participants into three arms to receive AMO959 with AAA617 and ARPI, AAA617 with ARPI, or other combinations, with treatments given in cycles up to six times every six weeks. Participants will receive study drugs in scheduled cycles and undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, dose adjustments, drug exposure, and biochemical responses such as PSA levels. Safety and treatment effects are tracked up to approximately 24 to 45 months. The study involves multiple visits for treatment and follow-up evaluations, measuring outcomes like progression-free survival, response rates, and quality of life.
Actively Recruiting
Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and patient-reported outcomes of a port delivery system PDS implant delivering ranibizumab for people with neovascular age-related macular degeneration nAMD. This study focuses on a 36-week refill schedule for the PDS implant filled with ranibizumab 100 mgmL. Participants include adults aged 50 and older with recent nAMD diagnosis and prior anti-VEGF treatment response. Participants will have the PDS implant surgically inserted in the study eye, containing approximately a 2-mg dose of ranibizumab. Based on disease activity at Week 24 or use of supplemental ranibizumab injections before Week 24, participants will receive implant refill exchanges every 24 weeks or every 36 weeks if disease activity criteria are not met. Supplemental intravitreal ranibizumab injections may be given as needed. During the study, participants will undergo regular assessments including visual acuity tests using the ETDRS chart and optical coherence tomography OCT imaging to monitor eye health and treatment effects. The study will track visual acuity changes, supplemental treatments, adverse events, and patient preferences over approximately 72 weeks. Safety and device-related events will be monitored up to around 19 months. The total participation duration aligns with the study completion date in 2028.
Actively Recruiting
Researchers are studying GSK5926371 in adults with autoimmune rheumatic diseases, including systemic lupus erythematosus, rheumatoid arthritis, idiopathic inflammatory myopathies, and Sjogrens disease. The trial aims to evaluate the safety, tolerability, how the body processes the drug, its effects, and any immune responses it may trigger. This is a Phase 1 interventional study sponsored by GlaxoSmithKline. The study has two parts Part 1 involves dose escalation to find a suitable priming dose of GSK5926371. In Part 2, participants receive doses based on findings from Part 1. GSK5926371 is administered as the investigational treatment throughout the study. The design is sequential, with dosing and evaluations adjusted according to initial results. Participants will be involved in clinic visits for drug administration, safety monitoring, and various assessments over up to 196 days. These include tracking adverse events, measuring drug levels in the blood, evaluating immune cell counts, antibody responses to the drug, immunoglobulin levels, vital signs, laboratory tests, and electrocardiograms. The study monitors participants closely to understand the drugs impact and safety profile.
Actively Recruiting
Researchers are evaluating how well elritercept works to improve anemia in adults with myelofibrosis MF who are already taking ruxolitinib. The study compares elritercept to a placebo and aims to learn if elritercept reduces tiredness, improves symptoms related to MF, helps participants be more active, and impacts the bone marrow and spleen. The safety of elritercept is also being assessed over a long period. This is a Phase 3, double-blind, randomized trial sponsored by Takeda. Participants will receive either elritercept or a matching placebo as a subcutaneous injection every 4 weeks for approximately 36 weeks during the double-blinded treatment period. Elritercept starts at a dose of 3.75 mgkg, with a possible increase to 5.0 mgkg from the third cycle based on response and safety. After this period, those on placebo may switch to elritercept during an extended open-label phase where dosing adjustments are also possible. During the study, participants will be monitored regularly with assessments including blood transfusion independence, fatigue levels, symptom scores, spleen size by imaging, and development of antibodies to the study drug. Researchers will track safety and overall survival for up to seven years. Participants can expect visits every 4 weeks during treatment, and the study includes long-term follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effects of dupilumab compared with placebo on airway inflammation, airway resistance, and lung remodeling in people aged 40 to 85 years with Chronic Obstructive Pulmonary Disease COPD. This Phase 4, multinational, randomized, double-blind, placebo-controlled study aims to understand how these changes relate to lung function, exacerbations, and quality of life improvements. Participants will receive subcutaneous injections of either dupilumab or placebo following the study protocol. The treatment period lasts up to 24 weeks within a total study duration of 40 weeks, during which participants will attend nine visits. The study includes detailed lung imaging assessments to measure mucus plugging and airway changes. During the study, participants will undergo evaluations including lung mucus scoring, high-resolution CT scans, and forced oscillation technique tests to monitor airway resistance and reactance. Safety is monitored by recording adverse events up to 36 weeks. The primary outcome is the change in global lung mucus score from baseline to Week 24. Participants will be followed for the full duration to assess treatment effects and safety.
1-10 of 47
1